Raymond James reinstated coverage of Sage Therapeutics with a Market Perform rating and no price target The firm continues to believe the postpartum depression opportunity for Zurzuvae is relatively modest and with shared economics, it struggles to see a path to profitability for the company. Furthermore, Sage’s pipeline “is thin with the recent notable setbacks,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $8 from $9 at Wedbush
- Sage Therapeutics price target lowered to $6 from $11 at BofA
- Sage Therapeutics price target lowered to $9 from $13 at Baird
- Sage study failure removes another potential upside driver, says Stifel
- Sage Therapeutics falls 21% after Phase 2 dalzanemdor results miss endpoint